- Company
- A change in the DPP4 diabetes market worth KRW 600 billion
- by Kim, Jin-Gu Apr 26, 2024 05:48am
- The market for DPRR-4 inhibitor class diabetes treatment, valued at KRW 600 billion annually, is undergoing a significant shift. Following the expiration of substance patents for major original products, generics have been launched, rapidly expanding their prescriptions. At the same time, the growth of original products is experiencing a sl
- Company
- ‘HTL is the best global partner for Korean companies'
- by Lee, Seok-Jun Apr 26, 2024 05:48am
- There is an easy way for domestic pharmaceutical companies wishing to go global: meet a partner that has extensive experience in entering the global market. The companies can speed up their global expansions by receiving the partner's know-how and minimizing trial and error. Time is money. Especially in the rapidly changing pharmaceutical and
- Company
- LG Chem-EuBiologics will locally manufacture vaccines
- by Kim, Jin-Gu Apr 26, 2024 05:47am
- LG Chem is joining hands with EuBiologics to speed up the development of pediatric combination vaccines that are being fully imported. LG Chem announced today that it has signed an agreement with EuBiologics to outsource the production of 'acellular Pertussis (aP)', the main antigen used for its hexavalent combination vaccine 'LR20062.
- Company
- Forxiga prescriptions 'drop' after a 'withdrawal notice'
- by Kim, Jin-Gu Apr 25, 2024 05:50am
- The prescription sales of ‘Forxiga (dapagliflozin),’ an SGLT-2 inhibitor class treatment for diabetes, have declined to 22% over a year. After announcing its withdrawal from the Korean market at the end of last year, the company has distributed only the remaining stocks of Forxiga in South Korea, which may have impacted prescription sales
- Company
- Godex’s sales slow down due to various regulatory measures
- by Chon, Seung-Hyun Apr 25, 2024 05:50am
- Celltrion’s liver drug 'Godex' is experiencing a slump in the prescription market. At one point, its quarterly prescription sales exceeded KRW 20 billion but have been on a downward trend for the past 2 years. The company has been able to pass the health authorities' reimbursement reevaluations, but the drug price cut that followed left a perfo
- Company
- Lipitor’s sales stay strong for good reason
- by Son, Hyung-Min Apr 25, 2024 05:50am
- The dyslipidemia treatment Lipitor has been able to remain the No. 1 selling drug for 20 years, supported by various clinical evidence. Lipitor has proven its efficacy in patients with dyslipidemia not only globally but also domestically. Based on various clinical evidence, major domestic and international societies still recommend statins a
- Company
- Possible reimb expansion for 2nd-gen BTK inhibitor Brukinsa
- by Eo, Yun-Ho Apr 25, 2024 05:50am
- The pharmaceutical industry is focusing on whether the second-generation BTK inhibitor 'Brukinsa' will overcome the last stage and acquire insurance reimbursement expansion. According to industry experts, BeiGene Korea is in negotiations with the National Health Insurance Service (NHIS) seeking approval for Brukinsa (zanubrutinib) in ma
- Company
- 19 K-biosimilar products sold in 11 markets after 12 yrs
- by Chon, Seung-Hyun Apr 25, 2024 05:49am
- Domestic pharmaceutical and biotech companies have succeeded in commercializing biosimilars in 11 areas. In the 12 years since Celltrion's Remsima was introduced, 19 biosimilars have received domestic approval. Among the companies, Samsung Bioepis has entered 9 markets, the most among Korean companies. According to the Ministry of Food and Dr
- Company
- Samsung Bioepis’ Stelara biosimilar is approved in Europe
- by Chon, Seung-Hyun Apr 24, 2024 05:44am
- Samsung Bioepis announced on the 23rd that the European Commission (EC) granted marketing authorization for its Stelara biosimilar Pyzchiva. The final marketing authorization comes 2 months after Pyzchiva received a positive opinion for marketing authorization from the European Medicines Agency (EMA)’s Committee for Medicinal Products
- Company
- Prostate cancer drug Pluvicto’s approval imminent in Korea
- by Eo, Yun-Ho Apr 24, 2024 05:44am
- The new metastatic castration-resistant prostate cancer drug ‘Pluvicto’ is set to soon be commercialized in Korea. According to industry sources, the Ministry of Food and Drug Safety is in the final stages of reviewing Novartis Korea's targeted radioligand therapy ‘Pluvicto (lutetium (177Lu) vipivotide tetraxetan)’ for its marketing a
